X0609 4 2026-06-01 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001758363 Turtle Cameron false 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 1 1 0 0 Chief Executive Officer 1 Common Stock 2026-06-01 4 S 0 3557 69.40 D 608983 D Common Stock 2026-06-01 4 S 0 8149 70.50 D 600834 D Common Stock 2026-06-01 4 S 0 3294 71.38 D 597540 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $68.96 to $69.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Includes 87,138 shares of common stock that vest in monthly installments through November 2026, subject to the continuing service of the Reporting Person on each vesting date. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.96 to $70.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.97 to $71.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Heidy King-Jones, as Attorney-in-Fact 2026-06-03